Eribulin mesylate - Eisai Co Ltd
At a glance
- Drug Originator Eisai Co Ltd; Harvard University; Japan Agency for Medical Research and Development
- Drug Licenced by Biotoscana; Equity Pharmaceuticals; Ewopharma; Neopharm Ltd; NewBridge Pharmaceuticals; PharmaSwiss; Viatris Inc
- Drug Class 2 ring heterocyclic compounds; Antineoplastics; Cyclic ethers; Furans; Ketones; Macrocyclic compounds; Small molecules
- Mechanism of Action Apoptosis stimulants; Cadherin modulators; Receptor protein-tyrosine kinase modulators; Transcription factor modulators; Tubulin polymerisation inhibitors
- USA Patent Applicants EISAI INC
- USA Patents 13
- NDAs 1
- International Patents 38
- Patent Applications 7
Disclaimer